A recent study indicates that people who stop using new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who stop conventional lifestyle plans.
Published data in a prominent medical journal demonstrates that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using these medications need to be informed of the risk of fast weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to starting mass in about a year and a half.
Weighing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, contrasted the effects of these new drugs with older methods.
The team point out that individuals who shed pounds through lifestyle changes alone usually experience a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors believe the mechanism of the injections explains the amplified regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, due to the high risk of relapse, the therapy should be considered life-long.
This perspective is echoed by drug manufacturers, who note that the results "emphasize the long-term nature of excess weight," similar to managing diseases like high blood pressure.
Patient Testimonies
Individuals who have stopped the medication report a powerful return of hunger.
"It felt as if something that goes on and I was suddenly starving," described one woman.
This challenge is worsened if users have not established permanent dietary or behavioural changes during therapy.
Growing Use
Figures show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among women compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent solution and lasting health benefits likely depends on combined lifestyle support.
